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INTRODUCTION 
Non alcoholic fatty liver disease[NAFLD] is emerging as most 
common liver disorder in India and other developing countries, The 
histological spectrum ranging from simple steatosis or steatosis with only 
mild inflammation    (type 1 and 2 NAFLD) to more severe steatohepatitis 
(types 3 and 4 NAFLD or NASH). Types 3 and 4 NAFLD progress to 
cirrhosis in 15-20% of patients. Progression is silent or paradoxically 
associated with normalization of aminotransferases. “NASH” coined by 
Ludwig and colleagues from Mayo clinic. 
SPECTRUM OF NAFLD 
• Steatosis  
• Steatohepatitis (NASH) 
• NASH with Fibrosis  
• Cirrhosis  
DEFINITIONS 
 NAFLD: Non alcoholic fatty infiltration with no or minimal inflammation 
and no fibrosis.also called simple steatosis,Pure steatosis and bland 
steatosis. 
2 
 
Primary NAFLD : indicates typical NAFLD associated with central 
obesity and T2 DM without specific etiology. 
Secondary NAFLD – associated with a specific, non alcohol related 
problem such as drugs or toxins. 
Toxin- associated steatohepatitis : associated with specific toxin or 
medication.eg petrochemical exposure in oil industry  
CRITERIA FOR DEFINING NAFLD 
1) A liver biopsy showing moderate to gross macrovesicular fatty 
change with or without inflammation (lobular or portal),and  
Mallory bodies, fibrosis, or cirrhosis. 
2)   No alcohol consumption or consumption less than 40 g of ethanol 
per week. 
3)   Absence of serologic evidence of hepatitis B or hepatitis C.  
EPIDEMIOLOGY AND PREVALENCE  
Prevalence of NAFLD 13-18% and that of NASH specifically 2-3% 
(1.2-9%) in two Japanese studies- incidence rate of 31 and 86 cases .  
( AGA guidelines 2012) 
The prevalence of NAFLD defined by USG -46% 
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By  histology confirmed NASH-12.2 %. (AGA guidelines 2012) It is 
a disease of all sexes, ethnicities, and age groups (peak 40-59) Higher in 
Hispanics than Africa Americans. Occurs more frequently in females (65 
to 83%) 
OBESITY 
 4.6 fold increase risk of fatty liver in USG compared to nonobese. 
Autopsy studies, steatosis-approx 70%obese vs 35% lean. Severe obesity 
patients- prevalance of NAFLD  may go upto 90%. Obese patients with 
abnormal liver enzymes approx 30% has septal fibrosis and 10% cirrhosis. 
INSULIN RESISTANCE AND T2 DM 
Insulin resistance is very common in NAFLD. Progression to overt  
iabetes is preceded by steatosis in susceptible  population. 75% of T2 DM- 
fatty infiltration. Liver injury worsens the preexistant diabetes in patients 
with NAFLD and doubles the prevalence of cirrhosis  from 10-25%. 
HYPERLIPIDEMIA 
2/3 of hypertriglyceridemeia&1/3rd with hypercholestrolemia- fatty 
liver Hyperlipidemia reported in 92% of NASH patients. Ethnic variation 
in lipid metabolism. Heterogenicity in lipid phenotypes in NAFLD 
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METABOLIC SYNDROME 
Steatosis and central adiposity with underlying insulin resistance and 
lipotoxicity- independent  risk factor for metabolic syndrome. Unexplained 
elevation of liver enzymes attributable to NAFLD seen in 7% of 
individuals with metabolic syndrome defined by adult Treatment Panel 111 
criteria.  
DIAGNOSIS 
On routine liver biochemical test elevated liver enzymes level 
usually will suspect common causes of liver disease will arose for other 
investigations like USG, CT, MRI, CBC, PT, anti-HCV, HBsAg, serum 
iron , anti-tripsin, ANA, on physical examination hepatomegaly, on history 
alcohol consumption should be   excluded [  less than  40 grams /week]  
clinically if the patients having  age > 50 years, obesity, diabetes, 
hypertension 
IMAGING  
Hepatic ultrasonogram shows “bright liver” with increased echoes 
consistant with steatosis on CT scan. Fatty liver shows lower in density 
compared to screen, MRI shows fat appears bright on T1 – weighted 
image, combination USG and CT have sensitivity 93 – 100% for detecting 
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hepatic fat, with more than grade I fatty liver [< 5% is minimal, 5 – 33% 
grade I, 33 – 66% grade II, > 66% grade III] with positive predictive value 
of 62 – 76%, no radiologic modality able to distinguish simple steatosis 
from more advanced NAFLD. These imaging techniques [USG, CT, MRI, 
support the diagnosis of NAFLD but it cannot predict the severity of 
disease. And also it cannot replace gold standard liver biopsy and 
histopathogy, for establishing diagnosis in certainty. 
So The degree of steatosis in NAFLD patients is usually assessed 
with invasive technique like liver biopsy, because of the invasive method 
of the liver biopsy and its painful  nature of the procedure with moderate 
complication rate need to find alternative less invasive, less painful, quick 
method to accurately diagnose NAFLD  
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
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AIMS AND OBJECTIVES 
To study and analyse  unenhanced CT [nc-CT] determination of 
hepatic steatosis based on image attenuation data (Hounsfield units) and to 
correlate it  with liver histopathology 
 
  
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
NAFLD is emerging as  one of the most common liver disorder in 
India and many other  developing countries in the world. The histological 
spectrum ranging from simple steatosis or steatosis with only mild 
inflammation( type 1 and 2 NAFLD) to more severe steatohepatitis (types 
3 and 4 NAFLD or NASH. Types 3 and 4 NAFLD progress to cirrhosis in 
15-20% of patients. Progression is silent or paradoxically associated with 
normalization of aminotransferases. “NASH” coined by Ludwig and 
colleagues from Mayo clinic. 
SPECTRUM OF NAFLD 
• Steatosis  
• Steatohepatitis (NASH) 
• NASH with Fibrosis   
• Cirrhosis 
DEFINIT 
  NAFLD: Non alcoholic fatty infiltration with no or minimal 
inflammation and no fibrosis. Also called simple steatosis, pure steatosis 
and bland steatosis. 
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Primary NAFLD: indicates typical NAFLD associated with central 
obesity and T2 DM without specific etiology. 
Secondary NAFLD – associated with a specific, on alcohol related 
problem such as drugs or toxins. 
Toxin- associated steatohepatitis: associated with specific toxin or 
medication.eg petrochemical exposure in oil industry  
CRITERIA FOR NAFLD 
1) A liver histology showing moderate to gross macro vesicular fatty 
change with or without inflammation (lobular or portal), and 
Mallory bodies, fibrosis, or cirrhosis. 
1)  No alcohol consumption or consumption less than 40 g of ethanol 
per week. 
2)   Absence of serologic evidence of hepatitis B or hepatitis C.  
EPIDEMIOLOGY AND PREVALENCE  
Prevalence of NAFLD 13-18% and that of NASH specifically 2-3% 
(1.2-9%) in two Japanese studies- incidence rate of 31 and 86 cases of 
suspected NAFLD person-years respectively. (AGA guidelines 2012) 
The prevalence by USG is-46% and the prevalence by histology -12.2 %. 
(AGA guidelines 2012) 
9 
 
It is a disease of both the sexes, ethnicities, and all age groups (peak 40-59) 
higher in Hispanics than Africa Americans. Occurs more frequently in 
females (65 to 83%) 
OBESITY 
4.6 Fold increase risk of fatty liver in USG compared to non obese. 
Autopsy studies, steatosis-approx 70%obese vs. 35% lean. Severe obesity 
patients- prevalence of NAFLD may go up to 90%. Obese patients with 
abnormal liver enzymes approx 30% have sepal fibrosis and 10% cirrhosis. 
INSULIN RESISTANCE AND T2 DM 
Insulin resistance is very common in NAFLD. Progression to overt 
diabetes is preceded by steatosis in susceptible population. 75% of T2 DM- 
fatty infiltration. Liver injury worsens the preexistent diabetes in patients 
with NAFLD and doubles the prevalence of cirrhosis from 10-25%. 
HYPERLIPIDEMIA 
2/3 of hypertriglyceridemeia&1/3rd with hypercholesterolemia- fatty 
liver Hyperlipidemia reported in 92% of NASH patients. Ethnic variation 
in lipid metabolism. Heterogenicity in lipid phenotypes in NAFLD 
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METABOLIC SYNDROME 
 Steatosis and central adiposity with underlying insulin resistance and 
lipotoxicity- independent risk factor for metabolic syndrome. Unexplained 
elevation of liver enzymes attributable to NAFLD seen in 7% of 
individuals with metabolic syndrome defined by adult Treatment Panel 111 
criteria. 
GENETIC AND FAMILIAL FACTORS 
Ethnic variation: Hispanic descent in USA has higher prevalence of 
NASH than primarily african-american descent. It reflects the ethnic 
difference in body fat distribution and lipoprotein metabolism. Familial 
factors: High prevalence in 1st degree relatives in NASH. Insulin resistance 
among relatives of T2DM and impaired skeletal muscle mitochondrial 
metabolism in offspring supports genetic component. Genetic variation: 
gene coding phospholipase like protein called PNPLA3 or adiponutrin – 
major predictor of steatosis in different ethnic groups. 
NASH in other liver diseases 
Steatosis mediated by core protein metabolism and microsomal TGL 
transfer protein associated with hepatitis C {geno3} infection. Obesity, 
insulin resistance negatively influences response to antiviral therapy. 
Occult hemochromatosis and iron loading – cofactor in progression of 
NASH. Steatosis –potential factor in progression of PBC. 
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ETIOLOGY 
Causes of Nonalcoholic Fatty Liver Disease 
Acquired Metabolic Disorders 
• Diabetes mellitus 
• Dyslipidemia 
• Kwashiorkor and marasmus 
• Obesity 
• Starvation 
Cytotoxic and Cytostatic Drugs 
Other Drugs and Toxins 
• Amiodarone 
• 4,4′-diethylaminoethoxyhexestrol 
• Dichlorethylene 
• Ethionine 
• Ethyl bromide 
• Estrogens 
• Glucocorticoids 
• Highly active antiretroviral therapy 
• Hydrazine 
• Hypoglycin 
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• Orotate 
• Perhexilene maleate 
• Safrole 
• Tamoxifen 
Acquired Metabolic Disorders 
• Diabetes mellitus 
• Dyslipidemia 
• Kwashiorkor and marasmus 
• Obesity 
• Starvation 
Acquired Metabolic Disorders 
• Diabetes mellitus 
• Dyslipidemia 
• Kwashiorkor and marasmus 
• Obesity 
• Starvation 
Cytotoxic and Cytostatic Drugs 
Other Drugs and Toxins 
• Amiodarone 
• 4,4′-diethylaminoethoxyhexestrol 
• Dichlorethylene 
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• Ethionine 
• Ethyl bromide 
• Estrogens 
• Glucocorticoids 
• Highly active antiretroviral therapy 
• Hydrazine 
• Hypoglycin 
• Orotate 
• Perhexilene maleate 
• Safrole 
• Tamoxifen 
Metals 
• Rare earths of low atomic number 
• Thallium compounds 
• Uranium compounds 
Inborn Errors of Metabolism 
• Abetalipoproteinemia 
• Familial hepatosteatosis 
• Galactosemia 
• Glycogen storage disease 
• Homocystinuria 
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• Systemic carnitine deficiency 
• Tyrosinemia 
• Weber-Christian syndrome 
• Wilson disease 
Surgical Procedures 
• Biliopancreatic diversion 
• Extensive small bowel resection 
• Gastric  and 
• Jejunoileal bypass 
Miscellaneous Conditions 
• Industrial exposure to petrochemicals 
• Inflammatory bowel disease 
• Partial lipodystrophy 
• Jejunal diverticulosis with bacterial overgrowth 
• Severe anemia 
• Total parenteral nutrition 
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PATHOGENESIS  OF NAFLD 
 
TRIGLYCERIDE ACCUMULATION 
Occurs due to shifting of fatty acid metabolism to lipogenesis and 
also synthesis of lipoprotein decreases  
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• Excessive importation of FFA  
Obesity  
• Impaired VLDL synthesis and secretion  
• Impaired beta-oxidation of FFA to ATP  
INSULIN RESISTANCE& HYPERINSULINEMIA 
It is a Primary pathogenic factor in steatosis. Excess FFA causes 
insulin resistance by  down regulating IRS-1 signaling. Insulin resistance 
potentiated by aberrant function of  peptide mediators TNF-α,leptin and 
adiponectin. TNF-α downregulates IRS-1 signaling via serine 
phosphorylation through activation of Jun terminal N kinase . Activation of 
inhibitor Kappa βkinase / nuclear factor kappa β  by FFA – reduce insulin 
sensitivity.  
LIPID PEROXIDATION & HEPATIC LIPOTOXICITY 
FFA upregulates cyst P-450 – enhanced generation of ROS & lipid 
per oxidation. Increase FFA concentration –sustained upregulation of 
PPAR-α-promotes fatty acid oxidation. FFA – direct toxicity to cell 
membrane- toxic fatty acid ethylesters formation – disruption of 
mitochondial function.  Adiponectin and Leptin  
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Other mechanisms 
• Portal endotoxemia  
• Oxidative stress- induction of cyt P450 2E1- generate ROS –
peroxidase cellular membrane- cell injury. 
• Mitochondrial changes 
    - Mitochondrial ROS formation 
    - Megamitochondria and crystalline inclusions 
    -Structural abnormalities 
    -Altered ATP homeostasis 
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Clinical features 
Clinical and Laboratory Features of Nonalcoholic Fatty Liver Disease 
SYMPTOMS SIGNS 
LAB 
FEATURES 
Common    
None (48-100%)   
Fatigue (70%) 
Hepatomegaly  
2 to 4 fold elevation of 
ALT/AST levels  
RUQ pain (50%)   AST/ALT ratio <1 
 Acantosis nigricans  S.ALP slightly elevated 
 
Occasional 
Neurological Deficits. 
In children 
Normal biluribin and 
albumin&PT levels  
Elevated serum ferritin 
levels.  
Increase in uric acid 
levels 
Uncommon    
Vague right upper 
quadrant pain  
Splenomegaly  
Low titre<1:320)ANA 
positivity  
Fatigue  Spider angiomata  
Elevated transferrin 
saturation  
Malaise  Palmar erythema  
HFE gene mutation 
( C282Y)  
 Ascites  
Elevation serum Ig A  
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NAFLD and Normal Aminotranferases 
• Occurs in later stages of steato hepatitis. 
• “True normal” in obese patients may be lower than that of lean 
individuals. 
• ALT levels are positively correlated with central obesity and 
hyperinsulinemia(leading to ongoing effort to revise normal 
changes). 
• Glitazones normalise transminase levels,but stil criteria for NASH 
met on follow up liver biopsy.  
Histopathology of NAFLD 
 
• Picture of simple steatosis or fatty liver. 
• Glycogenated nuclei seen. 
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NASH 
 
• “Lobular inflammation”   is hallmark.  
• Hepatocyte ballooning and necrosis of varying degrees present. 
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NASH with cirrhosis 
 
• NASH with cirrhosis  ( macrovesicular steatosis,inflammation and 
cirrhosis)  
• Early Cirrhosis (bridging fibrosis) 
• Masson trichrome staining. 
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• Mallory – Denken bodies – perinuclear material- dark staining 
brown masses. 
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Histological Features of NAFLD  
Present in All or Most Cases 
• Macrovesicular steatosis  
• Diffuse or centrilobular steatosis; degree may correlate with BMI 
• Parenchymal inflammation  
• Polymorphonuclear neutrophils, lymphocytes, other mononuclear 
cells 
• Hepatocyte necrosis 
• Ballooning hepatocyte degeneration 
Observed with Varied Frequencies 
• Perivenular, perisinusoidal, or periportal fibrosis (37%-84%), 
moderate to severe in 15%-50%; most prevalent in zone 3 
(perivenular) 
• Cirrhosis (7%-16% on index biopsy specimen) 
• Mallory bodies 
• Glycogenated nuclei 
• Lipogranulomas 
• Stainable hepatic iron 
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Risk Factors for Advanced Nonalcoholic Fatty Liver Disease 
Clinical 
• Older age (>50 years) 
• Obesity 
• Diabetes mellitus/insulin resistance 
• Hypertension 
Laboratory 
• AST/ALT ratio > 1 
• Serum ALT level > twice the upper limit of normal 
• Serum triglyceride levels > 155 mg/Dl 
Histologic 
• Severe steatosis 
• Necroinflammatory activity (hepatocyte ballooning, necrosis) 
• Stainable iron 
Diagnostic approach and evaluation of NAFLD. 
Essential Recording 
• Age, Gender 
• Body weight, body height, waist circumference, hip circumference, 
BMI 
• Alcohol consumption (amount/frequency,  at least g/day) 
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• History of liver disease, including HBV, HCV, autoimmune disease, 
DM, hyperlipidimia  
• Family History of above mentioned (at least first degree) 
NAFLD and Related Biochemical Studies Including OGTT and, IR 
• Arthrometry: BMI, Wait/hip ratio 
• AST/ALT, rGT, Bilirubin, ALP 
• Cholesterol, HDL, TG, UA 
• SBP/DBP 
• OGTT 
• Insulin Resistance 
• ANA, Ferritin  
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HOMA &QUICKI 
 
• Used to estimate insulin resistance by utilising mathematical 
manipulation of fasting insulin and glucose levels. 
• Homa index: insulin concentration (μU/ml)x fasting glucose 
concentration (mmol/l)/22.5 - utilise  
• Cutoff level: 2.5 for adult 
• Cutoff level: 3.16 for aldolescent  
• Keskin M, et al. Padiactric 2005 March 
• QUICKI ( quantitative insulin sensitivity index)- the addition 
of free fatty acid level in this will improve the accuracy 
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Diagnostic approach in suspected NAFLD 
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Role of Liver biopsy 
The only diagnostic test that quantifies hepatic steatosis,necrosis and 
fibrosis and histological stage of NAFLD is best prognostic indicator. 
 Indications in  
           NAFLD:  
    Peripheral stigmata of chronic liver disease  
    Splenomegaly  
    Cytopenia  
    Abnormal iron studies  
     Diabetes and/or significant obesity in an individual over the 
age of 45 
BIOPSY SCORING 
• NASH grade and stage(brunt) 0-8 
• NASH activity index ( NAI)- 0-12 accounts for steatosis, 
necroinflammatory and hepatocyte injury 
NAFLD activity score ( NAS)-0-8,steatosis 0-3,lobular and portal 
inflammation 0-3 cellular ballooning 0-2 
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NAFLD—Natural History 
• Steatosis generally follows a benign course 
• Steatosis can progress to NASH ±  fibrosis 
• NASH with fibrosis has increased liver-related morbidity and 
mortality 
• Olmsted large study 420pts with definite NAFLD on imaging and 
biopsy findings 
cirrhosis developed in 3% of patients. 
 132 patients of NAFLD followed for 18yrs. 
clinical outcomes based on  degree of injury on an index liver biopsy 
specimen. 
Cirrhosis and liver related death are common in NAFLD types 3 and 
4 than 1 and 2. 
• Studies show that long term survival of patients with NASH 
significantly better than alcoholic hepatitis . 
• 5-10yr outcome of NAFLD associated cirrhosis was similar to that 
for HCV associated cirrhosis, although HCC less common in 
patients with NAFLD. 
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• Studies show that long term survival of patients with NASH 
significantly better than alcoholic hepatitis . 
Independent predictors of fibrosis progression 
• Diabetes mellitus,  
• Low initial fibrosis stage 
• Higher body mass index.   
• Elevated liver enzymes  
Non invasive markers of fibrosis in NAFLD 
• Fibrotest: This tests incorporates haptoglobin,bil,GGTP,apo 
lipoproteinemiaA-1, α2 macroglobulin and necroinflammatory index 
combines above markers plus ALT levels.  cut off value – 0.70 has 
pos predictive value 
 NAFLD fibrosis score : incorporates age ,BMI,hyperglycemia, 
AST/ALT ratio, platelet count   and serum albumin level. PPV of 
82-90% 
•  Transient elastography (fibro scan) 
• S.dehydroepiandrosterone  
• S.hylaluronic acid levels. 
• Recently cytokeratin -18 level – novel biomarker for NASH 
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IMAGING OF NAFLD 
• USG abdomen -  “bright “ liver of increased echogenicity. 
Poor detection if the degree of steatosis is less than 20%  to 30%  
Initial test of choice for large population screening. 
 
• CT imaging : 
Sensitivity and specificity of detecting fatty liver (with spleen-
minus-liver attenuation of 10 Hounsfield units) were 0.84 and 0.99.  
liver: spleen ratio <1- steatosis  
• MRI : 
 T 1weighted image shows bright liver. 
Dixon technique provides qualitative assessment of TGL content. 
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 MR  proton spectroscopy : 
Newer tecnique of quantification of fatty infiltration.most accurate 
method of quantifying steatosis 
 
 
MR spectroscopy of TGL content in different ethnics 
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Currently non-invasive modalities are unable to detect NASH with 
or without fibrosis 
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MATERIAL AND METHODS 
The study was conducted at the department of Medical 
Gastroenterology, Institute of Pathology and in the Bernard Institute of 
Radiology  Department in the Rajiv Gandhi Government General Hospital 
Chennai. and in the Madras Medical College Chennai.,   
Patients coming to our OPD undergo routine  investigations like 
CBC,LFT,RFT,Blood sugar and USG Abdomen, among them those who 
had fatty liver on USG abdomen were selected,  those who with history of 
alcohol use and viral hepatitis were excluded  
Inclusion 
criteria 1. Fatty  liver on USG Abdomen  
Exclusion 
criteria 
 
1. Alcohol  (more  than 20 g/d) 
2. HCV  infection 
3. HBV  infection  
4. Decompensated  CLD 
5. HCC / focal lesion on USG or CT 
6. Coagulopathy ( for liver Bx) 
7. Secondary cause- surgery,  Drugs,  Pregnancy 
 
Total no of patients selected from the study is 30  
35 
 
Table 1  
 SEX DISTRIBUTION 
SEX DISTRIBUTION CASES 
MALE 15 
FEMALE 15 
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These  selected patient subjected to the following additional  
investigations Biochemical investigation – LFT. HBsAg, anti HCV,   BT, 
CT, PT/INR.   
       Detailed   history was taken and physical examinations done. All the 
patients underwent  non contrast CT [ncCT] scan. those patients  
underwent non contrast  computerized tomography of the abdomen with 
machine [GE Medical Systems, Milwaukee, WI] of Bernard Institute Of 
Radiology in Rajiv Gandhi Government General Hospital – Chennai . 
Following observation are assessed from the Radiology Department. 
With  Non contrast computerized tomography [nc CT]  CT attenuation 
index in houns field units [HU] of liver and  CT attenuation index in houns 
field units [HU] of spleen were assessed.  
All the patients after informed concern underwent liver biopsy after 
proper aseptic precaution and after screening for coagulation profile   in 
the side room of  ward no : 243 and 245 [male and female ward] of 
Medical Gastro Enterology Department Liver biopsy was done with biopsy 
true cut biopsy needle using biopsy gun, the specimen was  placed in 10% 
formalin and submitted for histologic examination. 
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LIVER BIOPSY GUN 
 
After the liver biopsy   all the patients were admitted and observed 
in the ward for 24 hrs.  Successful biopsy specimens were obtained in all 
the patients among them two patients  [mrs.Ayisha bevi and mr.Prasanth] 
required two pass for adequate biopsy sample size, other 28 patients 
required one pass only.  
Among them one patient [mrs.uniammal] developed severe pain 
after the procedure [pain radiating to right shoulder and became dyspneic ] 
she has been screened with X ray chest,  X ray erect abdomen and USG 
Abdomen .no evidence of any pneomothorax noted and the patient was 
managed symptomatically . no intervention required and sent home after 
48 hrs of observation.  
 
RESULTS 
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RESULTS 
This study includes total of 30 cases- CT Finding of six patients  
          
 Mrs.Muniammal                                      Mrs.Nisha  
          
 Mr.Prasanth                                  Mrs. Priya                                           
              
 Mr.Parthiban                    Mr.Vetri  selvan 
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Table 4 
CT Scan Finding of 30 patients –Attenuation in HOUNS FIELD 
UNITS [HU] 
NAME AGE SEX CT  HU Liver 
CT  HU 
spleen 
CT HU  
Liver-
spleen 
Raja  29 M 26 49 -23 
Banumathi  32 F 31 52 -21 
Devaki  60 F 26 45 -19 
Rangasamy  55 M 28 47 -19 
Yoganand  57 M 45 54 -9 
Aisha   bee 47 F 34 42 -8 
Purushothaman  39 M 36 48 -12 
Ladly  32 M 26 48 -22 
Ram  mohan  53 M 26 49 -23 
Prabha  44 F 26 48 -22 
Ramasamy  55 M 26 42 -6 
Ayisha  bevi 47 F 28 45 -17 
Prasanth  44 M 29 54 -25 
Jananki  39 F 26 42 -18 
Gopi  43 M 28 48 -20 
Nisha  47 F 26 57 -25 
Priya  34 F 34 51 -17 
Jothi  42 F 28 45 -17 
Amudha 48 F 28 45 -16 
Lalitha  51 F 28 45 -17 
Kumar  45 M 31 45 -14 
Muniammal  48 M 26 45 -19 
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Table 6 
One way ANOVA to compare mean values between Histology 
 Histology N Mean Std. Dev Min Max P-Value
CT HU  
Liver-spleen 
Minimal 5 13.00 4.36 8.00 18.00 
0.001 
Mild 9 15.11 4.17 6.00 19.00 
Moderate 12 20.25 2.05 17.00 23.00 
Severe 4 24.25 0.96 23.00 25.00 
Total 30 18.03 4.85 6.00 25.00 
 
Table 7 
 Tukey HSD Post Hoc Tests to compare multiple pairwise comparisons 
Dependent 
Variable 
Pairs 
Mean 
Difference 
P-Value 
CT HU  Liver-
spleen 
Minimal Mild -2.111 0.640 
Moderate -7.250 0.001 
Severe -11.250 0.001 
Mild Moderate -5.139 0.006 
Severe -9.139 0.001 
Moderate Severe -4.000 0.157 
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Tukey HSD Post Hoc Tests to compare multiple pairwise comparisons 
Dependent 
Variable 
Pairs 
Mean 
Difference 
P-Value 
Liver Spleen 
Ratio 
Minimal Mild 0.081 0.081 
Moderate 0.143 0.001 
Severe 0.222 0.001 
Mild Moderate 0.062 0.092 
Severe 0.141 0.002 
Moderate Severe 0.079 0.110 
 
Tukey HSD Post Hoc Tests to compare multiple pairwise comparisons 
Dependent 
Variable 
Pairs 
Mean 
Difference 
P-Value 
CT  HU Liver Minimal Mild 4.111 0.233 
Moderate 5.167 0.072 
Severe 6.250 0.090 
Mild Moderate 1.056 0.920 
Severe 2.139 0.783 
Moderate Severe 1.083 0.959 
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Tukey HSD Post Hoc Tests to compare multiple pairwise comparisons 
Dependent 
Variable 
Pairs 
Mean 
Difference 
P-Value 
BMI Minimal Mild -0.249 1.000 
Moderate 1.173 0.967 
Severe -1.660 0.954 
Mild Moderate 1.422 0.905 
Severe -1.411 0.960 
Moderate Severe -2.833 0.734 
Tukey HSD Post Hoc Tests to compare multiple pairwise comparisons 
Variable Pairs 
Mean 
Difference 
P-Value 
Liver Spleen Ratio Mild Moderate .05064 0.280 
Severe .06243 0.608 
Moderate Severe .01180 0.982 
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DISCUSSION 
The degree of steatosis in NAFLD patients is usually assessed with 
invasive technique like liver biopsy  [leon A.Adams,et al]7, Because of the 
invasive method of the liver biopsy and its painful  nature of the procedure 
with moderate complication rate there  has always been a need to find 
alternative less invasive, less painful, quick method to accurately diagnose 
NAFLD is the need of the hour. 
CT scan and MRI scan are well established imaging modalities for 
diagnosis of various  disorders. These imaging modalities can also assess 
the degree of fat as accurately as histology of liver tissue. This accuracy of 
grading of fatty liver by CT and MRI has been utilized by various 
investigators. Olmsted etal large study 420pts with definte NAFLD on 
imaging and liver biopsy. But only few studies are available [Nathan et al; 
sheela ramesh; arun j.sanyal et al]1,2,3. 
These authors tried to validate CT scan as non invasive diagnostic 
modality for this purpose, by comparing against gold standard liver biopsy. 
but their studies have been done in smallnumber  [ie., 15 subjects].  
Most of the studies are with magnetic resonance image [MRI].few 
studies are with computerized tomography [Nathan et al]1. These studies 
are also small in number. 
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In our study non contrast computerized tomography scan [nc CT] 
has been done in all the patients [no of sample size is 30] compared to 
previous studies the number is doubled. 
Initial evaluation of NAFLD requires ultra sound  scan of 
abdomen.just as  In previous studies  the investigators used USG for initial 
evaluation.  But this USG abdomen scan can be used for screening purpose 
only. It is not useful for semi quantitative assessment of steatosis.     
Non contrast CT scan [nc CT] has been  done in both the studies. 
Because non contrast CT scan will give accurate measurement of fat 
content of the liver measured as a hounce field unit is compared with 
nearby organ spleen. Both the studies [our study and the previous study] 
followed the same method. Use of contrast is avoided because contrast will 
decrease the liver attenuation in hounce field unit. It will give false positive 
results. 
The diagnostic sensitivity of the CT depends upon the severity of 
steatosis. HU will fall when more steatosis  is present in the liver. In the 
milder form of steatosis the HU will be in higher values or equal to spleen 
value. 
The study has confirmed the  nc CT is  useful  technique delineating  
macrosteatosis (HMS) in very high BMI P&S ,  CT with more HU unit 
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difference between CTHU liver to spleen is significantly and directly 
correlated to the histology in HMS. 
CT assessment of hepatic steatosis in previous studies was criticized 
on the basis of limited accuracy to estimate hepatic fat content accurately 
[etal] but such critisizism cannot be leveled with our datas  
Most of the studies conducted earlier [Nathan j.shore etal]1 is not a 
direct comparison between macrosteatosis to liver HU unit difference, only 
one study compared [Nathan et al] 1  hepatic macrosteatosis HMS to CT 
HU – liver difference, those studies are in small number. 
          The strength of this study,that it is a direct comparison of liver CT 
attenuation with histological grade of steatosis, it is not included the stage 
of fibrosis. In our study we have adopted grading of steatosis in four stages 
namely grade 0 is minimal <5 % of macrosteatosis, grade I is 5-33 % of 
macrosteatosis, grade II is 33-66 % of macrosteatosis, and grade III is 
more than 66 %  When   compared to  previous studies [Nathan j.shore 
etal]1 adapted hepatic macrsteatosis as more than 30 % [HMS].and this 
value has been compared to hepatic attenuation index in HU and also  there 
is no control arm in the previous mentioned studies [Nathan j.shore etal]1. 
To    delineate in which grade of HMS will directly correlate to hepatic CT 
attenuation index. 
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           Nathan j.shore etal1 in their study have  taken biopsy from both 
lobes of liver. And the biopsy is a wedge biopsy  taken  at the time of 
bariatric surgery. The tissue sample size is compared to our study is larger. 
And also they studied the liver  tissue triglyceride’s concentration by 
biochemical methods. But in our study biopsy has been taken by true cut 
needle biopsy using biopsy gun  and the tissue sample is small and only 
taken from the right lobe of the liver alone,  in this study no biochemical 
analysis of liver tissue is made ,the possibility of false negative results [ if 
the normal liver tissue in the biopsied sample ]could be possible and a false 
positive results [a focal nodular fatty liver]   may be another possibility to 
give grade III macro steatosis on histology. 
           Previous  study by qayyum etal. In his study he has included higher 
BMI patients only [BMI > 30] when compared to this study where in we 
have  included all the patients with BMI starting from 17.5 -  32 . In our 
study the inclusion criteria is based on the ultra sonogram finding of fatty 
liver. So that lean NASH can be calculated with our study. Out of 30 
patients lean NASH is [0 %]. 
           In various studies  sample size is  small less than 15 patients 
[Nathan j.shore etal]1compared to this study the sample size is 30 subjects. 
But one drawback of our study, there is no control arm, if a control arm is 
included we can accurately delineate at which liver HU difference  which 
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we can accurately predict the presence of NAFLD. It could served as a 
quantitative assessment of NAFLD score. The control arm was not 
designed due to the ethical point of view as well as risk of liver biopsy in 
normal subjects. Even though if the normal subject found to be detected 
having NAFLD. There is no definite treatment option available till Date. 
Also associated risk of radiation exposure in normal subjects for an 
investigation for a non clinical purpose. The studied patients under went 
plain CT abdomen, there is a life time risk of medical radiation but is a 
modest radiation exposure and also the abdominal region only exposed to 
radiation and not to the entire body.     
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CONCLUSION 
1]  There is definite correlation between non contrast computerized 
tomography [nc CT] with liver biopsy in this study [p value 0.001] 
2]  Hence  non contrast computerized tomography [nc CT] can be used 
as a sole investigation for defining NAFLD. invasive liver biopsy 
can be  used for borderline or indeterminate cases 
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ANNEXURES 
CONSENT FORM 
 
 
DESCRIPTION: You are invited to participate in a research study on liver disease.  
We are going to assess the normal values of liver biochemistry ,liver scan and liver 
tissue biopsy   in healthy adults. 
 
PROCEDURES: You will be asked to do ultra sound scan , CT-Scan,  Liver biopsy 
(small piece of liver tissue  by a small needle biopsy )and  Blood test provide a sample 
of blood (1 tablespoon).  The blood will be taken from your arm at the same time you 
are going to donate the blood. 
  
The results of the study of your samples will be used for research purposes only and 
you will not be told the results of the tests. 
RISKS AND BENEFITS:  there are mild  risks  of bleeding from liver puncture site 
associated pain with this study.  
 
TIME INVOLVEMENT: Post liver biopsy you have to stay for one day for 
observation of any complication  
 
PAYMENTS: You will not be paid to participate in this study. 
I, ____________________________________________ , hereby consent to do USG 
abdomen, CT abdomen , liver biopsy ,Blood sample which I have donated as a 
voluntarily  for the purpose of estimating the function of the liver in normal individuals. 
I have understood that this sample will be used for research and the results will not be 
available to me. I have also understood that this does not involve any additional 
procedure.  
 
Signature of the donor 
 
 
 Name of the Donor 
Witness – Signature, Name and address 
 
PROFORMA 
 
NAME  
AGE/SEX  
GE.No.  
CBC  
LFT  
PT/INR  
BT/CT  
HBsAg  
AntiHCV  
BLOOD SUGAR  
 F/PP 
 
BMI 
WAIST/HIP  
 
ALOHOL  CONSUPTION 
 QUANTITY IN GRAMS 
 
USG ABDOMEN  
CT ABDOMEN 
LIVER/SPLEEN RATIO 
LIVER-SPLEEN INDEX 
 
LIEVER BIOPSY 
LENGTH 
FINDING 
COPLICATION 
 
 
SL.No NAME AGE SEX HEIGHT WEIGHT BMI USG abdomen  CT  HU Liver CT  HU spleen CT HU  Liver‐spleen HISTOLOGY LFT1 LFT‐AST LFT‐ALT LFT‐SAP
1 raja 29 m 155 75 31.2 3 26 49 ‐23 3 1.12 25.7 39.9 131
2 banumathi 32 f 155 70 29.1 1 31 52 ‐21 2 1.4 29 32 120
3 devaki 60 f 152 68 29.4 2 26 45 ‐19 2 0.9 34 42 92
4 rangasamy 55 m 168 72 25.5 1 28 47 ‐19 1 0.9 30 23 83
5 yoganand 57 m 168 80 28.3 2 45 54 ‐9 0 1.1 23 29 92
6 aisha bee 47 f 150 72 32 1 34 42 ‐8 0 0.7 59 44 152
7 purushothaman 39 m 169 80 28 1 36 48 ‐12 1 0.9 36 39 75
8 ladly 32 m 152 70 30.3 2 26 48 ‐22 2 1.1 94 86 132
9 ram mohan 53 m 155 69 28.7 1 26 49 ‐23 2 1.3 21 26 102
10 prabha 44 f 153 45 19.2 2 26 48 ‐22 2 1 56 76 134
11 ramasamy 55 m 165 50 18.4 3 26 42 ‐6 1 0.7 34 36 120
12 ayisha bevi 47 f 156 69 28.4 1 28 45 ‐17 1 1.2 29 23 84
13 prasanth 44 m 160 65 25.4 2 29 54 ‐25 3 0.9 102 109 196
14 jananki 39 f 158 50 20 1 26 42 ‐18 0 0.7 34 31 98
15 gopi 43 m 162 52 19.8 1 28 48 ‐20 2 0.8 34 36 102
16 nisha 47 f 158 71 28.4 2 26 57 ‐25 3 4.1 32 34 98
17 priya 34 f 157 68 27.6 2 34 51 ‐17 2 0.7 231 246 163
18 jothi 42 f 154 48 20.2 2 28 45 ‐17 2 0.8 24 19 98
19 amudha 48 f 160 48 18.7 2 28 45 ‐16 1 2.1 19 17 102
20 lalitha 51 f 149 63 28.4 1 28 45 ‐17 1 0.8 83 96 159
21 kumar 45 m 162 54 20.6 2 31 45 ‐14 0 1.8 19 17 109
22 muniammal 48 m 158 70 28 1 26 45 ‐19 1 0.8 64 96 128
23 yogas 57 m 168 70 24.8 1 32 45 ‐13 1 0.9 124 34 102
24 vetriselvan 35 m 159 53 21 2 26 56 ‐24 3 1.8 34 31 103
25 vijayalakshmi 39 f 155 56 23.3 1 29 45 ‐16 0 0.7 96 96 104
26 sangeetha 40 f 154 62 26.1 2 29 48 ‐19 2 2.1 19 20 96
27 noorjagan 42 f 150 42 17.5 2 26 48 ‐19 2 0.9 47 51 102
28 anandvalli 45 f 143 68 25.6 1 28 45 ‐17 1 1.2 29 34 106
29 thiru 51 m 167 47 17.7 2 26 48 ‐22 2 1 34 39 123
30 parthiban 54 m 165 50 18.4 2 28 50 ‐22 2 1 29 34 96
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